About this event
The therapeutic potential of cell therapies is an established fact, but whether will they be able to overcome challenges posed by Solid Tumors remains a question. With innovative strategies, many types of cell therapies are being developed by Industry and academia with a focus on succeeding in Solid tumors. Engineered receptors (like CAR/ TCR), novel gene-editing techniques (CRISPR/ Transposons/ lentiviral, etc), scaling processes, etc are being developed to actualize the dream of transforming patients' treatment through cell therapies.
Let's explore the upcoming disruptive innovations that will bring about a paradigm shift in the development and success of cell therapies in solid tumors.
FutureBridge’s Oncology Analysts in this webinar will cover:
Hosted by
I am a Life science specialist with a PhD in clinical Biochemistry and hold a keen interest and passion for immuno-oncology. Associated to FutureBridge (oncology consulting) for providing on-demand and strategic insights on new evolving scientific technologies and innovations.
A molecular biologist with expertise in oncology business research and consulting, R&D strategy, and competitive and treatment landscapes for companies developing oncology assets.
I am life sciences professional with ~20 years overall experience in drug discovery, pharma, oncology/immuno-oncology consulting. I provide consultation to global clients to support their strategic business decisions.
FutureBridge is a techno-commercial consulting and advisory company.
We track and advise on the future of industries from a 1-to-25-year perspective to keep you ahead of the technology curve, propel your growth, Identify new opportunities, markets and business models, answer your unknowns, and fac